title: Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy.
abstract: The aim of this study describes the creation of superhigh-magnetization nanocarriers (SHMNCs) comprised of a magnetic Fe(3)O(4) (SHMNPs) core and a shell of aqueous stable self-doped poly[N-(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (∼27.1 wt%) of doxorubicin (DOX). The SHMNCs display superparamagnetic property with a magnetization of 89.7 emu/g greater than that of Resovist (a commercial contrast agent used for magnetic resonance imaging; 73.7 emu/g). Conjugating the anticancer drug DOX to these nanocarriers enhances the drug's thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX. The high R2 relaxivity (434.7 mM(-1)s(-1)) of SHMNCs not only be a most effective MT carrier of chemotherapeutic agent but be an excellent contrast agent of MRI, allowing the assessment of the distribution and concentration of DOX in various tissues and organs. This advanced drug delivery system promises to provide more effective MT therapy and tumor treatment using lower therapeutic doses and potentially reducing the side effects of cardiotoxicity caused by DOX.
authors.affiliation: Molecular Medicine Research Center, Department of Chemical and Materials Engineering, Chang Gung University, Kuei-Shan, Tao-Yuan, Taiwan, ROC. huamy@mail.cgu.edu.tw
authors.forename: Mu-Yi
authors.initials: MY
authors.lastname: Hua
authors.forename: Hung-Wei
authors.initials: HW
authors.lastname: Yang
authors.forename: Hao-Li
authors.initials: HL
authors.lastname: Liu
authors.forename: Rung-Ywan
authors.initials: RY
authors.lastname: Tsai
authors.forename: See-Tong
authors.initials: ST
authors.lastname: Pang
authors.forename: Kun-Lung
authors.initials: KL
authors.lastname: Chuang
authors.forename: Yu-Sun
authors.initials: YS
authors.lastname: Chang
authors.forename: Tsong-Long
authors.initials: TL
authors.lastname: Hwang
authors.forename: Ying-Hsu
authors.initials: YH
authors.lastname: Chang
authors.forename: Heng-Chang
authors.initials: HC
authors.lastname: Chuang
authors.forename: Cheng-Keng
authors.initials: CK
authors.lastname: Chuang
mesh_terms: D000814:Aniline Compounds / Q000737:chemistry; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology; D045744:Cell Line, Tumor; D003287:Contrast Media / Q000737:chemistry; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D052203:Ferrosoferric Oxide / Q000737:chemistry*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D059346:Magnets / Q000737:chemistry; D051379:Mice; D049329:Nanostructures / Q000737:chemistry / Q000648:ultrastructure; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000814:Aniline Compounds; D000903:Antibiotics, Antineoplastic; D003287:Contrast Media; D004317:Doxorubicin; D052203:Ferrosoferric Oxide